Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22059Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Rizos, C. V. | en |
| dc.contributor.author | Milionis, H. J. | en |
| dc.contributor.author | Kostapanos, M. S. | en |
| dc.contributor.author | Florentin, M. | en |
| dc.contributor.author | Kostara, C. E. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.contributor.author | Liberopoulos, E. N. | en |
| dc.date.accessioned | 2015-11-24T19:20:44Z | - |
| dc.date.available | 2015-11-24T19:20:44Z | - |
| dc.identifier.issn | 1879-114X | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22059 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Antihypertensive Agents/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Benzimidazoles/adverse effects/pharmacology/therapeutic use | en |
| dc.subject | Benzoates/adverse effects/pharmacology/therapeutic use | en |
| dc.subject | Biphenyl Compounds/adverse effects/pharmacology/therapeutic use | en |
| dc.subject | Blood Glucose/*drug effects | en |
| dc.subject | C-Reactive Protein/drug effects/metabolism | en |
| dc.subject | Drug Therapy, Combination | en |
| dc.subject | Fasting | en |
| dc.subject | Female | en |
| dc.subject | Fluorobenzenes/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Greece | en |
| dc.subject | Homeostasis/drug effects | en |
| dc.subject | Humans | en |
| dc.subject | Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse | en |
| dc.subject | effects/*pharmacology/therapeutic use | en |
| dc.subject | Hyperlipidemias/complications/drug therapy | en |
| dc.subject | Hypertension/complications/drug therapy | en |
| dc.subject | Imidazoles/adverse effects/pharmacology/therapeutic use | en |
| dc.subject | Insulin/blood | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Prospective Studies | en |
| dc.subject | Pyrimidines/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Sulfonamides/adverse effects/*pharmacology/therapeutic use | en |
| dc.subject | Tetrazoles/adverse effects/pharmacology/therapeutic use | en |
| dc.title | Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.clinthera.2010.03.018 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20399986 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0149291810001098/1-s2.0-S0149291810001098-main.pdf?_tid=d4d6bd9ba8b37e11adbb82ba38a71f1f&acdnat=1333968443_8f8d37ff65a358f5b884f98dac36a483 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2010 | - |
| heal.abstract | BACKGROUND: Statin therapy has been reported to be associated with new-onset diabetes. Angiotensin II-receptor blockers (ARBs) are effective antihypertensive drugs that have been reported to activate peroxisome proliferator-activated receptor gamma (PPARgamma) to differing extents, with favorable effects on glucose metabolism and the incidence of new-onset diabetes. Among the ARBs, telmisartan is a partial activator of PPARgamma, irbesartan is a weak partial activator, and olmesartan has no effect on PPARgamma activation. OBJECTIVE: The goal of this study was to evaluate the effects on glucose homeostasis of combining rosuvastatin with ARBs of varying PPARgamma-activating potency in Greek adults with impaired fasting glucose, mixed dyslipidemia, and stage 1 hypertension. METHODS: This was a 24-week, randomized, open-label study. Inclusion criteria were impaired fasting plasma glucose (FPG) (100-125 mg/dL [5.6-6.9 mmol/L]), mixed dyslipidemia (LDL-C >160 mg/dL [4.14 mmol/L] and triglycerides >150 mg/dL [1.69 mmol/L]), and stage 1 hypertension (systolic blood pressure 140-159 mm Hg and/or diastolic blood pressure 90-99 mm Hg). After 12 weeks of dietary intervention, patients were randomly allocated to receive rosuvastatin 10 mg/d plus telmisartan 80 mg/d (RT group), irbesartan 300 mg/d (RI group), or olmesartan 20 mg/d (RO group) for 24 weeks. The primary end point was change in the following indices of glucose metabolism after 6 months of treatment: FPG, homeostasis model assessment of insulin resistance (HOMA-IR), HOMA of beta-cell function (HOMA-B), and glycosylated hemoglobin (HbA(1c)). Secondary end points included changes in anthropometric variables, blood pressure, serum lipids, and high-sensitivity C-reactive protein (hs-CRP). Tolerability was monitored throughout the study. RESULTS: After the 12-week dietary intervention, 151 white patients (78 female, 73 male) met the inclusion criteria and were randomized to receive RT (n = 52), RI (n = 48), or RO (n = 51). The mean (SD) age of the 3 groups was 60 (10), 60 (10), and 58 (12) years, respectively; their mean weight was 79 (11), 81 (12), and 78 (11) kg. At 6 months, the RT group had a 29% decrease in HOMA-IR (from a median [range] of 2.6 [0.6-6.6] to 1.8 [0.5-5.1]), the RI group had a 16% increase (from 2.5 [0.5-6.2] to 2.9 [0.5-8.1]), and the RO group had a 14% increase (from 2.4 [0.5-7.9] to 2.7 [0.5-5.2]) (all, P < 0.05 vs baseline). The improvement in the RT group was statistically significant compared with the RI group (P < 0.01) and the RO group (P < 0.05). The changes from baseline in FPG and HbA(1c) were not significant in any group. Fasting serum insulin decreased by 21% in the RT group (from 10.4 [2.4-28.1] to 8.2 [2.4-18.8] microU/mL), whereas it increased by 12% in the RI group (from 9.1 [2.0-26.5] to 10.2 [2.0-25.2] microU/mL) and by 8% in the RO group (from 10.1 [2.0-29.6] to 10.9 [2.0-19.1] microU/mL) (all, P < 0.05 vs baseline). Again, there was a significant difference between the RT group and the RI group (P < 0.01) and RO group (P < 0.05). Levels of hs-CRP decreased by 44% in the RT group (from 2.2 [0.3-7.9] to 1.2 [0.4-7.0] mg/L), by 12% in the RI group (from 2.2 [0.3-12.3] to 1.9 [0.2-11.4] mg/L), and by 22% in the RO group (from 2.1 [0.7-4.0] to 1.7 [0.7-6.2] mg/L). The difference was statistically significant for the RT group compared with baseline and with the RI and RO groups (all comparisons, P < 0.05). Blood pressure was significantly reduced from baseline in all 3 groups, with no significant differences between groups. No serious adverse events were reported during the study, nor were there any clinically significant elevations in aminotransferases or creatine kinase. CONCLUSION: In this small, randomized, open-label study, the RT combination had favorable effects on HOMA-IR, fasting serum insulin, and hs-CRP compared with the RI and RO combinations in Greek adults with impaired fasting glucose, mixed hyperlipidemia, and stage 1 hypertension. | en |
| heal.journalName | Clin Ther | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Rizos-2010-Effects of rosuvasta.pdf | 860.71 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
